Land: Malta
Taal: Engels
Bron: Malta Medicines Authority
CYTISINE
Aflofarm Farmacja Polska SP. zo.o. ul. Partyzancka 133/151 95-200 Pabianice, Poland
N07BA04
CYTISINE 1.5 mg
TABLET
CYTISINE 1.5 mg
POM
OTHER NERVOUS SYSTEM DRUGS
Licence number in the source country: NOT APPLICAPABLE
Authorised
2022-02-17
1 PACKAGE LEAFLET: INFORMATION FOR THE USER NOVYNTA, 1.5 MG, TABLETS Cytisine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Novynta is and what it is used for 2. What you need to know before you use Novynta 3. How to use Novynta 4. Possible side effects 5. How to store Novynta 6. Contents of the pack and other information 1. WHAT NOVYNTA IS AND WHAT IT IS USED FOR Smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of Novynta is the permanent cessation of the nicotine-containing products use. The use of Novynta allows for a gradual reduction of nicotine dependence by relieving withdrawal symptoms. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE NOVYNTA DO NOT USE NOVYNTA: - if you are allergic to cytisine or any of the other ingredients of this medicine (listed in section 6), - if you have unstable angina, - if you have a history of recent myocardial infarction, - if you have clinically significant cardiac arrhythmias, - if you had stroke recently, - if you are pregnant or breast-feeding. WARNINGS AND PRECAUTIONS Novynta should be used with caution in case of ischemic heart disease, heart failure, hypertension, pheochromocytoma (a tumour of the adrenal gland), atherosclerosis (hardening of the arteries) and other peripheral vascular diseases, gastric and duodenal ulcer, gastroesophageal reflux disease, hyperthyroidism (overactive thy Lees het volledige document
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Novynta, 1.5 mg, tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 1.5 mg of cytisine. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Round, biconvex, white tablet with diameter 6 mm. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of Novynta is the permanent cessation of the nicotine-containing products use. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology One package of Novynta (100 tablets) is sufficient for a complete treatment course. The duration of therapy is 25 days. Novynta should be taken according to the following schedule: _ _ DAYS OF TREATMENT RECOMMENDED DOSING MAXIMUM DAILY DOSE From the 1st to the 3rd day 1 tablet every 2 hours 6 tablets From the 4th to the 12th day 1 tablet every 2.5 hours 5 tablets From the 13th to the 16th day 1 tablet every 3 hours 4 tablets From the 17th to the 20th day 1 tablet every 5 hours 3 tablets From the 21st to the 25th day 1-2 tablets a day to 2 tablets Smoking should be stopped no later than on the 5th day of treatment. Smoking should not be continued during treatment as this may aggravate adverse reactions (see section 4.4). In case of treatment failure, the treatment should be discontinued and may be resumed after 2 to 3 months. _Special population (renal impairment, hepatic impairment) _ There is no clinical experience of Novynta in patients with renal or hepatic impairment, therefore the drug product is not recommended for use in this patient population. _Elderly population _ Due to limited clinical experience, Novynta is not recommended for use in elderly patients over 65 years of age. 2 _Paediatric population _ The safety and efficacy of Novynta in persons under 18 years of age have not been established. Novynta is not recommended for use in persons under 18 years of age. Method of administration Novynta should be ta Lees het volledige document